Patents by Inventor Kathryn A. Hanley

Kathryn A. Hanley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
    Patent number: 11753627
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: September 12, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein
    Patent number: 11318196
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 3, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1,2,3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1,2,3, AND 4
    Publication number: 20200392469
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 17, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
    Patent number: 10837003
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 17, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20200085939
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
    Patent number: 10500264
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: December 10, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1, 2, 3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 4
    Publication number: 20180010099
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Application
    Filed: September 20, 2017
    Publication date: January 11, 2018
    Applicant: The United States of America,as represented by the Secretary, Department of Helath and Human Service
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20180008693
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 11, 2018
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
    Patent number: 9783787
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: October 10, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein
    Patent number: 9707287
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof. The invention further features an attenuated dengue virus comprising a proline to leucine change at amino acid position 2343 of non-structural protein 4B (NS4B), wherein the numbering is based upon the prototypic isolate DEN4 Dominica 1981 and the attenuated mutant DEN virus has at least one of the following properties: improved replication in Vero cells or restricted replication in mosquito cells.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: July 18, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20150064214
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: December 4, 2013
    Publication date: March 5, 2015
    Applicant: The USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3? untranslated region
    Patent number: 8632782
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 21, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1, 2, 3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 4
    Publication number: 20130011433
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Application
    Filed: November 28, 2011
    Publication date: January 10, 2013
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20120114694
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 10, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
    Patent number: 8075903
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: December 13, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
  • Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
    Patent number: RE45016
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Attenuated dengue virus comprising mutations in the NS3 gene
    Patent number: RE45053
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 29, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Recombinant attenuated dengue viruses comprising a deletion in the 3? untranslated region and additional attenuating mutations induced by chemical mutagenesis
    Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
    Patent number: RE46631
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 12, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
    Patent number: RE46641
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 19, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai